- Report
- July 2024
- 153 Pages
Global
From €3309EUR$3,613USD£2,813GBP
€3893EUR$4,250USD£3,309GBP
- Report
- February 2025
- 45 Pages
United States
From €1104EUR$1,205USD£938GBP
- Report
- January 2024
- 80 Pages
Poland
From €1374EUR$1,500USD£1,168GBP
- Report
- January 2024
- 80 Pages
Argentina
From €1374EUR$1,500USD£1,168GBP
- Report
- December 2023
- 132 Pages
Global
From €870EUR$950USD£740GBP
- Report
- August 2024
- 295 Pages
Global
From €1702EUR$1,859USD£1,447GBP
€2432EUR$2,655USD£2,067GBP
- Report
- September 2024
- 280 Pages
Global
From €1702EUR$1,859USD£1,447GBP
€2432EUR$2,655USD£2,067GBP
- Report
- August 2024
- 290 Pages
Global
From €1702EUR$1,859USD£1,447GBP
€2432EUR$2,655USD£2,067GBP
- Report
- December 2022
- 439 Pages
Global
From €2289EUR$2,499USD£1,946GBP
€3270EUR$3,570USD£2,779GBP
- Report
- July 2022
- 256 Pages
Global
From €2289EUR$2,499USD£1,946GBP
€3270EUR$3,570USD£2,779GBP
- Report
- July 2022
- 290 Pages
Global
From €2216EUR$2,419USD£1,883GBP
€3166EUR$3,456USD£2,691GBP
- Report
- March 2022
- 157 Pages
Global
From €2380EUR$2,598USD£2,023GBP
€3400EUR$3,712USD£2,890GBP
- Report
- August 2021
- 187 Pages
Global
From €2380EUR$2,598USD£2,023GBP
€3400EUR$3,712USD£2,890GBP
- Book
- May 2021
- 224 Pages
- Book
- March 2014
- 144 Pages
- Book
- September 2013
- 152 Pages

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more